Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
Colorcon
McKinsey
Moodys
Boehringer Ingelheim

Last Updated: December 6, 2019

DrugPatentWatch Database Preview

SOLIFENACIN SUCCINATE Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Solifenacin Succinate patents expire, and what generic alternatives are available?

Solifenacin Succinate is a drug marketed by Ajanta Pharma Ltd, Alembic Pharms Ltd, Alkem Labs Ltd, Amneal Pharms Co, Breckenridge, Celltrion, Cipla, Glenmark Pharms Inc, Jiangxi Boya Seehot, Msn Labs Pvt Ltd, Qilu Pharm Co Ltd, Sciegen Pharms Inc, Strides Pharma, Teva Pharms Usa, Unichem Labs Ltd, and Watson Labs Inc. and is included in sixteen NDAs.

The generic ingredient in SOLIFENACIN SUCCINATE is solifenacin succinate. There are thirty drug master file entries for this compound. Twenty-three suppliers are listed for this compound. There is one tentative approval for this compound. Additional details are available on the solifenacin succinate profile page.

Drug patent expirations by year for SOLIFENACIN SUCCINATE
Drug Prices for SOLIFENACIN SUCCINATE

See drug prices for SOLIFENACIN SUCCINATE

Recent Clinical Trials for SOLIFENACIN SUCCINATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Fundacion para la Formacion e Investigacion Sanitarias de la Region de MurciaPhase 4
Ono Pharmaceutical Co. LtdPhase 2
Bangabandhu Sheikh Mujib Medical University, Dhaka, BangladeshPhase 4

See all SOLIFENACIN SUCCINATE clinical trials

Recent Litigation for SOLIFENACIN SUCCINATE

Identify potential future generic entrants

District Court Litigation
Case NameDate
Astellas Pharma Inc. v. Aurobindo Pharma Limited2018-06-25
Astellas Pharma Inc. v. Cipla Limited2018-06-05

See all SOLIFENACIN SUCCINATE litigation

Pharmacology for SOLIFENACIN SUCCINATE
Medical Subject Heading (MeSH) Categories for SOLIFENACIN SUCCINATE
Synonyms for SOLIFENACIN SUCCINATE
(1S)-(3R)-1-azabicyclo[2.2.2]oct-3-yl-3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylate succinate
(1S)-3,4-Dihydro-1-phenyl-d5-2(1H)-isoquinolinecarboxylic Acid (3R)-1-Azabicyclo-[2.2.2]oct-3-yl Ester Hydrochloride
[(3R)-1-azabicyclo[2.2.2]octan-3-yl] (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate; butanedioic acid
[(3R)-1-azabicyclo[2.2.2]octan-3-yl] (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate;butanedioic acid
[(3R)-quinuclidin-3-yl] (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate; succinic acid
1-azabicyclo[2.2.2]octan-3-yl (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate; butanedioic acid
1-azabicyclo[2.2.2]octan-3-yl 1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate; butanedioic acid
1-Azabicyclo[2.2.2]octan-8-yl (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate butanedioic acid
1-Azabicyclo[2.2.2]octan-8-yl (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate butanedioic acid (Solifenacin?Succinate)
2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-, (3R)-1-azabicyclo(2.2.2)oct-3-yl ester, (1S)-, butanedioate (1:1)
242478-38-2
A817166
A819262
AB0139087
AC-747
AC1L50Q6
AC1L9FFO
AC1Q5VRD
AK160479
AKOS005146515
AKOS015896172
AKOS015994745
AM84825
AN-15595
AS-12203
AS-35288
AX8032830
BC677662
BCP21989
Butanedioic acid, cmpd. with (1S)-(3R)-1-azabicyclo(2.2.2)oct-3-yl 3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylate (1:1)
Butanedioic acid, compd with (1S)-(3R)-1-azabicyclo(2.2.2)oct-3-yl 3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylate (1:1)
butanedioic acid; (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylic acid [(3R)-1-azabicyclo[2.2.2]octan-3-yl] ester
butanedioic acid; 1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylic acid 1-azabicyclo[2.2.2]octan-3-yl ester
C23H26N2O2.C4H6O4
CHEBI:32151
CHEMBL1200803
CS-0371
CTK8G3169
D01269
FT-0657634
HY-A0002
I06-1672
KKA5DLD701
KS-00000656
KS-1286
LS-183550
MLS006010416
MolPort-003-850-268
MolPort-009-682-972
PubChem18822
PubChem20236
Q-101001
quinuclidin-3-yl (1S)-1-phenyl-3,4-dihydroisoquinoline-2(1H)-carboxylate succinate
Quinuclidin-3'-yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylatemonosuccinate
RL02770
RXZMMZZRUPYENV-VROPFNGYSA-N
S0944
s3048
SB17428
SCHEMBL109333
SCHEMBL111525
SCHEMBL6478242
SMR004701445
Solifenacin (Succinate)
Solifenacin for system suitability, EuropePharmacopoeia (EP) Reference Standard
Solifenacin succinate (JAN/USAN/INN)
Solifenacin succinate [USAN]
Solifenacin Succinate Salt
Solifenacin succinate, >=98% (HPLC)
Solifenacin succinate, EuropePharmacopoeia (EP) Reference Standard
Solifenacin Succinate, United States Pharmacopeia (USP) Reference Standard
ST24049293
SW219141-1
UNII-KKA5DLD701
Vesicare
Vesicare (TN)
Vesicare OD
Vesikur
W-5423
YM 905
YM-53705
YM-67905
YM-905
YM67905
YM905
Paragraph IV (Patent) Challenges for SOLIFENACIN SUCCINATE
Tradename Dosage Ingredient NDA Submissiondate
VESICARE TABLET;ORAL solifenacin succinate 021518 2009-04-08

US Patents and Regulatory Information for SOLIFENACIN SUCCINATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Watson Labs Inc SOLIFENACIN SUCCINATE solifenacin succinate TABLET;ORAL 202551-002 May 20, 2019 AB RX No No   Start Trial   Start Trial   Start Trial
Teva Pharms Usa SOLIFENACIN SUCCINATE solifenacin succinate TABLET;ORAL 091464-002 Apr 2, 2014 AB RX No No   Start Trial   Start Trial   Start Trial
Unichem Labs Ltd SOLIFENACIN SUCCINATE solifenacin succinate TABLET;ORAL 211701-001 Aug 27, 2019 AB RX No No   Start Trial   Start Trial   Start Trial
Ajanta Pharma Ltd SOLIFENACIN SUCCINATE solifenacin succinate TABLET;ORAL 205483-001 May 20, 2019 AB RX No No   Start Trial   Start Trial   Start Trial
Jiangxi Boya Seehot SOLIFENACIN SUCCINATE solifenacin succinate TABLET;ORAL 210281-002 May 20, 2019 AB RX No No   Start Trial   Start Trial   Start Trial
Sciegen Pharms Inc SOLIFENACIN SUCCINATE solifenacin succinate TABLET;ORAL 211657-002 May 20, 2019 AB RX No No   Start Trial   Start Trial   Start Trial
Amneal Pharms Co SOLIFENACIN SUCCINATE solifenacin succinate TABLET;ORAL 209719-001 May 20, 2019 AB RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
Colorcon
Harvard Business School
Medtronic
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.